medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-14-40-44medalphabet-3249Research ArticleСтатьиПредикторы перехода ремиттирующего рассеянного склероза во вторично-прогрессирующийPredictors of transition from relapsing‑remitting multiple sclerosis to secondary progressivehttps://orcid.org/0000-0001-8317-7060УрбанМ. А.UrbanM. A.

Урбан Мария Анатольевна - аспирант кафедры неврологии, нейрохирургии и медицинской генетики.

Ижевск

Maria A. Urban - postgraduate student of Dept of Neurology, Neurosurgery and Medical Genetics.

Izhevsk

https://orcid.org/0000-0002-7104-2377КомиссароваН. В.KomissarovaN. V.

Комиссарова Наталия Валерьевна - кандидат медицинских наук, заведующий кафедрой неврологии, нейрохирургии и медицинской генетики.

Ижевск

Natalia V. Komissarova - PhD Med, head of Dept of Neurology, Neurosurgery and Medical Genetics.

Izhevsk

https://orcid.org/0000-0001-5733-8924ХазиеваИ. И.KhazievaI. I.

Хазиева Илюса Ильсуровна - студентка V курса лечебного факультета.

Ижевск

Ilyusa I. Khazieva - 4th year student of Faculty of Medicine.

Izhevsk

ilusa_x_2000@mail.ruhttps://orcid.org/0000-0003-1972-4888ШамсутдиноваИ. И.ShamsutdinovaI. I.

Шамсутдинова Ильнара Илсуровна - студентка V курса лечебного факультета.

Ижевск

Ilnara I. Shamsutdinova - 4th year student of Faculty of Medicine.

Izhevsk

ФГБОУ ВПО «Ижевская государственная медицинская академия» Минздрава РоссииРоссияIzhevsk State Medical AcademyRussian Federation202319102023014«Неврология и психиатрия» (2)4044Copyright © Урбан М.А., Комиссарова Н.В., Хазиева И.И., Шамсутдинова И.И., 20232023Урбан М.А., Комиссарова Н.В., Хазиева И.И., Шамсутдинова И.И.Urban M.A., Komissarova N.V., Khazieva I.I., Shamsutdinova I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3249

В настоящее время рассеянный склероз (РС) является второй по частоте причиной инвалидизации лиц молодого возраста после травмы [1]. Примерно 85 % пациентов с РС имеют ремиттирующее течение, которое в половине случаев в течение 15–20 лет переходит в неуклонное прогрессирование с сохранением активности или без нее в виде обострений или новых активных очагов. Диагностика вторично-прогрессирующего РС (ВПРС) затруднена, и диагноз ВПРС ставится ретроспективно. Поэтому мы в нашей статье рассматриваем варианты надежных и объективных биомаркеров, которые служат предикторами конверсии и являются источниками для перспективного прогнозирования заболевания.

Currently, the multiple sclerosis (MS) is the second most common cause of disability in young people after injury [1]. Approximately 85 % of patients with MS have a relapsing course, which in a half of cases occurs within 15–20 years, culminating in steady progression with or without activity remaining in the form of an exacerbation or new active foci. Diagnosis of secondary progressive MS (SPMS) is difficult and the diagnosis of SPMS is made retrospectively. Therefore, in our article, we considered options for reliable and objective biomarkers that are natural predictors of conversion and are sources for long-term prediction of diseases.

ремиттирующий рассеянный склерозвторично-прогрессирующий рассеянный склерозпредикторырасширенная шкала инвалидностиФункциональный комплекс рассеянного склерозабиомаркерremitting multiple sclerosissecondary progressive multiple sclerosispredictorsexpanded disability status scalemultiple sclerosis functional complexbiomarkerReferencesSawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol. (2014) 13: 700–9. https://doi.org/10.1016/s1474–4422(14)70041–9Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol. (2014) 13: 700–9. https://doi.org/10.1016/s1474–4422(14)70041–9Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and meta-analyses. Lancet Neurol. (2015) 14: 263–73. https://doi.org/10.1016/s1474–4422(14)70267–4Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and meta-analyses. Lancet Neurol. (2015) 14: 263–73. https://doi.org/10.1016/s1474–4422(14)70267–4Katz Sand I. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol. (2015) 28: 193–205. https://doi.org/10.1097/wco.0000000000000206Katz Sand I. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol. (2015) 28: 193–205. https://doi.org/10.1097/wco.0000000000000206Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. (1983) 33: 1444–52. https://doi.org/10.1212/wnl.33.11.1444Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. (1983) 33: 1444–52. https://doi.org/10.1212/wnl.33.11.1444Cadavid D, Tang Y, O'Neill G. Responsiveness of the expanded disability status scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Rev Neurol. (2010) 51: 321–9. https://doi.org/10.33588/rn.5106.2010390Cadavid D, Tang Y, O'Neill G. Responsiveness of the expanded disability status scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Rev Neurol. (2010) 51: 321–9. https://doi.org/10.33588/rn.5106.2010390Hyland M, Rudick RA. Challenges to clinical trials in multiple sclerosis: Outcome measures in the era of disease-modifying drugs. Curr Opin Neurol. (2011) 24: 255–61. https://doi.org/10.1097/wco.0b013e3283460542Hyland M, Rudick RA. Challenges to clinical trials in multiple sclerosis: Outcome measures in the era of disease-modifying drugs. Curr Opin Neurol. (2011) 24: 255–61. https://doi.org/10.1097/wco.0b013e3283460542Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, et al. Assessing disability progression with the multiple sclerosis functional composite. Mult Scler. (2009) 15: 984–97. https://doi.org/10.1177/1352458509106212Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, et al. Assessing disability progression with the multiple sclerosis functional composite. Mult Scler. (2009) 15: 984–97. https://doi.org/10.1177/1352458509106212Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol. (1988) 45: 746–8. https://doi.org/10.1001/archneur.1988.00520310052017Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol. (1988) 45: 746–8. https://doi.org/10.1001/archneur.1988.00520310052017Demir S. Multiple Sclerosis Functional Composite. Noro Psikiyatr Ars. (2018) 55 (Suppl. 1): S 66–S 8. https://doi.org/10.29399/npa.23349Demir S. Multiple Sclerosis Functional Composite. Noro Psikiyatr Ars. (2018) 55 (Suppl. 1): S 66–S 8. https://doi.org/10.29399/npa.23349Bin Sawad A, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. Evaluation of the expanded disability status scale and the multiple sclerosis functional composite as clinical endpoints in multiple sclerosis clinical trials: Quantitative meta-analyses. Curr Med Res Opin. (2016) 32: 1969–74. https://doi.org/10.1080/03007995.2016.1222516Bin Sawad A, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. Evaluation of the expanded disability status scale and the multiple sclerosis functional composite as clinical endpoints in multiple sclerosis clinical trials: Quantitative meta-analyses. Curr Med Res Opin. (2016) 32: 1969–74. https://doi.org/10.1080/03007995.2016.1222516Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. (2017) 23: 94–105. https://doi.org/10.1177/1352458516638941Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. (2017) 23: 94–105. https://doi.org/10.1177/1352458516638941Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20 % worsening on timed 25-foot walk and 9-hole peg test in multiple sclerosis. Mult Scler. (2006) 12: 594–8. https://doi.org/10.1177/1352458506070768Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20 % worsening on timed 25-foot walk and 9-hole peg test in multiple sclerosis. Mult Scler. (2006) 12: 594–8. https://doi.org/10.1177/1352458506070768Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, et al. Progression on the multiple sclerosis functional composite in multiple sclerosis: what is the optimal cut-off for the three components? Mult Scler. (2010) 16: 862–7. https://doi.org/10.1177/1352458510370464Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, et al. Progression on the multiple sclerosis functional composite in multiple sclerosis: what is the optimal cut-off for the three components? Mult Scler. (2010) 16: 862–7. https://doi.org/10.1177/1352458510370464Rudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: A new clinical outcome measure for multiple sderosis trials. Mult Scler. (2002) 8: 359–65. https://doi.org/10.1191/1352458502ms845oaRudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: A new clinical outcome measure for multiple sderosis trials. Mult Scler. (2002) 8: 359–65. https://doi.org/10.1191/1352458502ms845oaOrbach R, Zhao Z, Wang YC, O'Neill G, Cadavid D. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS ONE. (2012) 7: e45409. https://doi.org/10.1371/journal.pone.0045409Orbach R, Zhao Z, Wang YC, O'Neill G, Cadavid D. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS ONE. (2012) 7: e45409. https://doi.org/10.1371/journal.pone.0045409Rosti-Otajarvi E, Hamalainen P, Koivisto K, Hokkanen L. The reliability of the MSFC and its components. Acta Neurol Scand. (2008) 117: 421–7. https://doi.org/10.1111/j.1600–0404.2007.00972Rosti-Otajarvi E, Hamalainen P, Koivisto K, Hokkanen L. The reliability of the MSFC and its components. Acta Neurol Scand. (2008) 117: 421–7. https://doi.org/10.1111/j.1600–0404.2007.00972Solari A, Radice D, Manneschi L, Motti L, Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci. (2005) 228: 71–4. https://doi.org/10.1016/j.jns.2004.09.033Solari A, Radice D, Manneschi L, Motti L, Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci. (2005) 228: 71–4. https://doi.org/10.1016/j.jns.2004.09.033Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. (2002) 59: 679–87. https://doi.org/10.1212/wnl.59.5.679Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. (2002) 59: 679–87. https://doi.org/10.1212/wnl.59.5.679Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. (2018) 24: 1665–80. https://doi.org/10.1177/1352458518803785Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. (2018) 24: 1665–80. https://doi.org/10.1177/1352458518803785Messinis L, Kosmidis MH, Lyros E, Papathanasopoulos P. Assessment and rehabilitation of cognitive impairment in multiple sclerosis. Int Rev Psychiatry. (2010) 22: 22–34. https://doi.org/10.3109/09540261003589372Messinis L, Kosmidis MH, Lyros E, Papathanasopoulos P. Assessment and rehabilitation of cognitive impairment in multiple sclerosis. Int Rev Psychiatry. (2010) 22: 22–34. https://doi.org/10.3109/09540261003589372Hojsgaard Chow H, Schreiber K, Magyari M, Ammitzboll C, Bornsen L, Romme Christensen J, et al. Progressive multiple sclerosis, cognitive function, and quality of life. Brain Behav. (2018) 8: e00875. https://doi.org/10.1002/brb3.875Hojsgaard Chow H, Schreiber K, Magyari M, Ammitzboll C, Bornsen L, Romme Christensen J, et al. Progressive multiple sclerosis, cognitive function, and quality of life. Brain Behav. (2018) 8: e00875. https://doi.org/10.1002/brb3.875Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernandez Perez MA, Meca-Lallana V, Ramio-Torrenta L. Cognitive dysfunctions and assessments in multiple sclerosis. Front Neurol. (2019) 10: 581. https://doi.org/10.3389/fneur.2019.00581Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernandez Perez MA, Meca-Lallana V, Ramio-Torrenta L. Cognitive dysfunctions and assessments in multiple sclerosis. Front Neurol. (2019) 10: 581. https://doi.org/10.3389/fneur.2019.00581Manca R, Stabile MR, Bevilacqua F, Cadorin C, Piccione F, Sharrack B, et al. Cognitive speed and white matter integrity in secondary progressive multiple sclerosis. Mult Scler Relat Disord. (2019) 30: 198–207. https://doi.org/10.1016/j.msard.2019.02.021Manca R, Stabile MR, Bevilacqua F, Cadorin C, Piccione F, Sharrack B, et al. Cognitive speed and white matter integrity in secondary progressive multiple sclerosis. Mult Scler Relat Disord. (2019) 30: 198–207. https://doi.org/10.1016/j.msard.2019.02.021Eijlers AJC, van Geest Q, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, et al. Predicting cognitive decline in multiple sclerosis: A 5-year follow-up study. Brain. (2018) 141: 2605–18. https://doi.org/10.1093/brain/awy202Eijlers AJC, van Geest Q, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, et al. Predicting cognitive decline in multiple sclerosis: A 5-year follow-up study. Brain. (2018) 141: 2605–18. https://doi.org/10.1093/brain/awy202Van Schependom J, D'Hooghe M B, Cleynhens K, D'Hooge M, Haelewyck MC, De Keyser J, et al. The symbol digit modalities test as sentinel test for cognitive impairment in multiple sclerosis. Eur J Neurol. (2014) 21: 1219–25. e71–2. https://doi.org/10.1111/ene.12463Van Schependom J, D'Hooghe M B, Cleynhens K, D'Hooge M, Haelewyck MC, De Keyser J, et al. The symbol digit modalities test as sentinel test for cognitive impairment in multiple sclerosis. Eur J Neurol. (2014) 21: 1219–25. e71–2. https://doi.org/10.1111/ene.12463Giordano A, Colombo B, Spinelli EG, Gelibter S, Guerrieri S, Leocani L, et al. Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report. Mult Scler Relat Disord. (2018) 24:69–71. https://doi.org/10.1016/j.msard.2018.06.011Giordano A, Colombo B, Spinelli EG, Gelibter S, Guerrieri S, Leocani L, et al. Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report. Mult Scler Relat Disord. (2018) 24:69–71. https://doi.org/10.1016/j.msard.2018.06.011Ikuta F, Zimmerman HM. Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States. Neurology. (1976) 26 (6 Pt. 2): 26–8. https://doi.org/10.1212/wnl.26.6_part_2.26Ikuta F, Zimmerman HM. Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States. Neurology. (1976) 26 (6 Pt. 2): 26–8. https://doi.org/10.1212/wnl.26.6_part_2.26Galetta KM, Balcer LJ. Measures of visual pathway structure and function in MS: clinical usefulness and role for MS trials. Mult Scler Relat Disord. (2013) 2: 172–82. https://doi.org/10.1016/j.msard.2012.12.004Galetta KM, Balcer LJ. Measures of visual pathway structure and function in MS: clinical usefulness and role for MS trials. Mult Scler Relat Disord. (2013) 2: 172–82. https://doi.org/10.1016/j.msard.2012.12.004Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. (2007) 114: 1804–9. https://doi.org/10.1016/j.ophtha.2007.06.047Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. (2007) 114: 1804–9. https://doi.org/10.1016/j.ophtha.2007.06.047Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler. (2017) 23: 734–47. https://doi.org/10.1177/1352458517690822Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler. (2017) 23: 734–47. https://doi.org/10.1177/1352458517690822Talman LS, Bisker ER, Sackel DJ, Long DA Jr, Galetta KM, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol. (2010) 67: 749–60. https://doi.org/10.1002/ana.22005Talman LS, Bisker ER, Sackel DJ, Long DA Jr, Galetta KM, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol. (2010) 67: 749–60. https://doi.org/10.1002/ana.22005Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Henderson SB, et al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology. (2012) 119: 1250–7. https://doi.org/10.1016/j.ophtha.2011.11.032Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Henderson SB, et al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology. (2012) 119: 1250–7. https://doi.org/10.1016/j.ophtha.2011.11.032Reich DS, Smith SA, Gordon-Lipkin EM, Ozturk A, Caffo BS, Balcer LJ, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol. (2009) 66: 998–1006. https://doi.org/10.1001/archneurol.2009.107Reich DS, Smith SA, Gordon-Lipkin EM, Ozturk A, Caffo BS, Balcer LJ, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol. (2009) 66: 998–1006. https://doi.org/10.1001/archneurol.2009.107Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, et al. Contrast letter acuity as a visual component for the multiple sclerosis functional composite. Neurology. (2003) 61: 1367–73. https://doi.org/10.1212/01.wnl.0000094315.19931.90Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, et al. Contrast letter acuity as a visual component for the multiple sclerosis functional composite. Neurology. (2003) 61: 1367–73. https://doi.org/10.1212/01.wnl.0000094315.19931.90Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. (2005) 64: 992–5. https://doi.org/10.1212/01.wnl.0000154521.40686.63Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. (2005) 64: 992–5. https://doi.org/10.1212/01.wnl.0000154521.40686.63Bsteh G, Hegen H, Ladstatter F, Berek K, Amprosi M, Wurth S, et al. Change of olfactory function as a marker of inflammatory activity and disability progression in MS. Mult Scler. (2019) 25: 267–74. https://doi.org/10.1177/1352458517745724Bsteh G, Hegen H, Ladstatter F, Berek K, Amprosi M, Wurth S, et al. Change of olfactory function as a marker of inflammatory activity and disability progression in MS. Mult Scler. (2019) 25: 267–74. https://doi.org/10.1177/1352458517745724Carotenuto A, Costabile T, Moccia M, Falco F, Scala MR, Russo CV, et al. Olfactory function and cognition in relapsing-remitting and secondary-progressive multiple sclerosis. Mult Scler Relat Disord. (2019) 27: 1–6. https://doi.org/10.1016/j.msard.2018.09.024Carotenuto A, Costabile T, Moccia M, Falco F, Scala MR, Russo CV, et al. Olfactory function and cognition in relapsing-remitting and secondary-progressive multiple sclerosis. Mult Scler Relat Disord. (2019) 27: 1–6. https://doi.org/10.1016/j.msard.2018.09.024Bsteh G, Berek K, Hegen H, Teuchner B, Auer M, Wurth S, et al. Smelling multiple sclerosis: different qualities of olfactory function reflect either inflammatory activity or neurodegeneration. Mult Scler. (2020) 26: 57–68. DOI: 10.1177/1352458518814113.Bsteh G, Berek K, Hegen H, Teuchner B, Auer M, Wurth S, et al. Smelling multiple sclerosis: different qualities of olfactory function reflect either inflammatory activity or neurodegeneration. Mult Scler. (2020) 26: 57–68. DOI: 10.1177/1352458518814113.Silva AM, Santos E, Moreira I, Bettencourt A, Coutinho E, Goncalves A, et al. Olfactory dysfunction in multiple sclerosis: Association with secondary progression. Mult Scler. (2012) 18: 616–21. https://doi.org/10.1177/1352458511427156Silva AM, Santos E, Moreira I, Bettencourt A, Coutinho E, Goncalves A, et al. Olfactory dysfunction in multiple sclerosis: Association with secondary progression. Mult Scler. (2012) 18: 616–21. https://doi.org/10.1177/1352458511427156Rolet A, Magnin E, Millot JL, Berger E, Vidal C, Sileman G, et al. Olfactory dysfunction in multiple sclerosis: Evidence of a decrease in different aspects of olfactory function. Eur Neurol. (2013) 69: 166–70. https://doi.org/10.1159/000345482Rolet A, Magnin E, Millot JL, Berger E, Vidal C, Sileman G, et al. Olfactory dysfunction in multiple sclerosis: Evidence of a decrease in different aspects of olfactory function. Eur Neurol. (2013) 69: 166–70. https://doi.org/10.1159/000345482Sastre-Garriga J, Pareto D, Rovira A. Brain atrophy in multiple sclerosis: clinical relevance and technical aspects. Neuroimaging Clin N Am. (2017) 27: 289–300. https://doi.org/10.1016/j.nic.2017.01.002Sastre-Garriga J, Pareto D, Rovira A. Brain atrophy in multiple sclerosis: clinical relevance and technical aspects. Neuroimaging Clin N Am. (2017) 27: 289–300. https://doi.org/10.1016/j.nic.2017.01.002De Stefano N, Battaglini M, Smith SM. Measuring brain atrophy in multiple sclerosis. J Neuroimaging. (2007) 17 (Suppl. 1): 10S-5S. https://doi.org/10.1111/j.1552–6569.2007.00130De Stefano N, Battaglini M, Smith SM. Measuring brain atrophy in multiple sclerosis. J Neuroimaging. (2007) 17 (Suppl. 1): 10S-5S. https://doi.org/10.1111/j.1552–6569.2007.00130Amiri H, de Sitter A, Bendfeldt K, Battaglini M, Gandini Wheeler-Kingshott CAM, Calabrese M, et al. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. Neuroimage Clin. (2018) 19: 466–75. https://doi.org/10.1016/j.nicl.2018.04.023Amiri H, de Sitter A, Bendfeldt K, Battaglini M, Gandini Wheeler-Kingshott CAM, Calabrese M, et al. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. Neuroimage Clin. (2018) 19: 466–75. https://doi.org/10.1016/j.nicl.2018.04.023Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. (2002) 17: 479–89. https://doi.org/10.1006/nimg.2002.1040Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. (2002) 17: 479–89. https://doi.org/10.1006/nimg.2002.1040Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. (2001) 25: 466–75. https://doi.org/10.1097/00004728–200105000–00022Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. (2001) 25: 466–75. https://doi.org/10.1097/00004728–200105000–00022Smeets D, Ribbens A, Sima DM, Cambron M, Horakova D, Jain S, et al. Reliable measurements of brain atrophy in individual patients with multiple sclerosis. Brain Behav. (2016) 6: e00518. https://doi.org/10.1002/brb3.518Smeets D, Ribbens A, Sima DM, Cambron M, Horakova D, Jain S, et al. Reliable measurements of brain atrophy in individual patients with multiple sclerosis. Brain Behav. (2016) 6: e00518. https://doi.org/10.1002/brb3.518Durand-Dubief F, Belaroussi B, Armspach JP, Dufour M, Roggerone S, Vukusic S, et al. Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: Comparison of 7 quantification techniques. AJNR Am J Neuroradiol. (2012) 33: 1918–24. https://doi.org/10.3174/ajnr.A3107Durand-Dubief F, Belaroussi B, Armspach JP, Dufour M, Roggerone S, Vukusic S, et al. Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: Comparison of 7 quantification techniques. AJNR Am J Neuroradiol. (2012) 33: 1918–24. https://doi.org/10.3174/ajnr.A3107Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol. (2018) 83: 210–22. https://doi.org/10.1002/ana.25145Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol. (2018) 83: 210–22. https://doi.org/10.1002/ana.25145Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. (2017) 16: 797–812. https://doi.org/10.1016/S1474–4422(17)30278–8Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. (2017) 16: 797–812. https://doi.org/10.1016/S1474–4422(17)30278–8Chawla S, Kister I, Wuerfel J, Brisset JC, Liu S, Sinnecker T, et al. Iron and non-iron-related characteristics of multiple sclerosis and neuromyelitis optical lesions at 7T MRI. AJNR Am J Neuroradiol. (2016) 37: 1223–30. https://doi.org/10.3174/ajnr.a4729Chawla S, Kister I, Wuerfel J, Brisset JC, Liu S, Sinnecker T, et al. Iron and non-iron-related characteristics of multiple sclerosis and neuromyelitis optical lesions at 7T MRI. AJNR Am J Neuroradiol. (2016) 37: 1223–30. https://doi.org/10.3174/ajnr.a4729Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. (2000) 157: 267–76. https://doi.org/10.1016/s0002–9440(10)64537–3Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. (2000) 157: 267–76. https://doi.org/10.1016/s0002–9440(10)64537–3Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. (2018) 14: 577–89. https://doi.org/10.1038/s41582–018–0058-zKhalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. (2018) 14: 577–89. https://doi.org/10.1038/s41582–018–0058-zDisanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. (2017) 81: 857–70. https://doi.org/10.1002/ana.24954Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. (2017) 81: 857–70. https://doi.org/10.1002/ana.24954Novakova L, Zetterberg H, Sundstrom P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. (2017) 89: 2230–7. https://doi.org/10.1212/wnl.0000000000004683Novakova L, Zetterberg H, Sundstrom P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. (2017) 89: 2230–7. https://doi.org/10.1212/wnl.0000000000004683Bhan A, Jacobsen C, Myhr KM, Dalen I, Lode K, Farbu E. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler. (2018) 24: 1301–7. https://doi.org/10.1177/1352458518782005Bhan A, Jacobsen C, Myhr KM, Dalen I, Lode K, Farbu E. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler. (2018) 24: 1301–7. https://doi.org/10.1177/1352458518782005Ferrazzano G, Crisafulli SG, Baione V, Tartaglia M, Cortese A, Frontoni M, et al. Early diagnosis of secondary progressive multiple sclerosis: Focus on fluid and neurophysiological biomarkers. J Neurol. (2020). https://doi.org/10.1007/s00415–020–09964–4Ferrazzano G, Crisafulli SG, Baione V, Tartaglia M, Cortese A, Frontoni M, et al. Early diagnosis of secondary progressive multiple sclerosis: Focus on fluid and neurophysiological biomarkers. J Neurol. (2020). https://doi.org/10.1007/s00415–020–09964–4Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. (2019) 92: e1007–15. https://doi.org/10.1212/wnl.0000000000007032Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. (2019) 92: e1007–15. https://doi.org/10.1212/wnl.0000000000007032Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. (2018) 141: 2382–91. https://doi.org/10.1093/brain/awy154Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. (2018) 141: 2382–91. https://doi.org/10.1093/brain/awy154Sellebjerg F, Royen L, Soelberg Sorensen P, Oturai AB, Jensen PEH. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Mult Scler. (2019) 25: 1444–51. https://doi.org/10.1177/1352458518794308Sellebjerg F, Royen L, Soelberg Sorensen P, Oturai AB, Jensen PEH. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Mult Scler. (2019) 25: 1444–51. https://doi.org/10.1177/1352458518794308Ferraro D, Guicciardi C, De Biasi S, Pinti M, Bedin R, Camera V, et al. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. Acta Neurol Scand. (2020) 141: 16–21. https://doi.org/10.1111/ane.13152Ferraro D, Guicciardi C, De Biasi S, Pinti M, Bedin R, Camera V, et al. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. Acta Neurol Scand. (2020) 141: 16–21. https://doi.org/10.1111/ane.13152Kalatha T, Hatzifilippou E, Arnaoutoglou M, Balogiannis S, Koutsouraki E. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort. Hell J Nucl Med. (2019) 22 (Suppl. 2): 113–21.Kalatha T, Hatzifilippou E, Arnaoutoglou M, Balogiannis S, Koutsouraki E. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort. Hell J Nucl Med. (2019) 22 (Suppl. 2): 113–21.Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. (2015) 38: 364–74. https://doi.org/10.1016/j.tins.2015.04.003Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. (2015) 38: 364–74. https://doi.org/10.1016/j.tins.2015.04.003Williams A, Piaton G, Lubetzki C. Astrocytes – friends or foes in multiple sclerosis? Glia. (2007) 55: 1300–12. https://doi.org/10.1002/glia.20546Williams A, Piaton G, Lubetzki C. Astrocytes – friends or foes in multiple sclerosis? Glia. (2007) 55: 1300–12. https://doi.org/10.1002/glia.20546Correale J, Farez MF. The role of astrocytes in multiple sclerosis progression. Front Neurol. (2015) 6: 180. https://doi.org/10.3389/fneur.2015.00180Correale J, Farez MF. The role of astrocytes in multiple sclerosis progression. Front Neurol. (2015) 6: 180. https://doi.org/10.3389/fneur.2015.00180Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathol. (2010) 119: 7–35. https://doi.org/10.1007/s00401–009–0619–8Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathol. (2010) 119: 7–35. https://doi.org/10.1007/s00401–009–0619–8Novakova L, Axelsson M, Malmestrom C, Imberg H, Elias O, Zetterberg H, et al. Searching for neurodegeneration in multiple sclerosis at clinical onset: diagnostic value of biomarkers. PLoS ONE. (2018) 13: e0194828. https://doi.org/10.1371/journal.pone.0194828Novakova L, Axelsson M, Malmestrom C, Imberg H, Elias O, Zetterberg H, et al. Searching for neurodegeneration in multiple sclerosis at clinical onset: diagnostic value of biomarkers. PLoS ONE. (2018) 13: e0194828. https://doi.org/10.1371/journal.pone.0194828Axelsson M, Malmestrom C, Nilsson S, Haghighi S, Rosengren L, Lycke J. Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis. J Neurol. (2011) 258: 882–8. https://doi.org/10.1007/s00415–010–5863–2Axelsson M, Malmestrom C, Nilsson S, Haghighi S, Rosengren L, Lycke J. Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis. J Neurol. (2011) 258: 882–8. https://doi.org/10.1007/s00415–010–5863–2Hogel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler. (2020) 26: 210–9. https://doi.org/10.1177/1352458518819380Hogel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler. (2020) 26: 210–9. https://doi.org/10.1177/1352458518819380Абрамова А. А., Закройщикова И. В., Кротенкова И. А., Кочергин И. А., Захарова М. Н. Эктопические лимфоидные В-клеточные фолликулы при рассеянном склерозе: роль в патогенезе заболевания и прогностическая значимость. Журнал неврологии и психиатрии им. С. С. Корсакова. 2019; 119 (10, вып. 2): 21–27. https://doi.org/10.17116/jnevro201911910221Abramova A. A., Zakroishchikova I. V., Krotenkova I. A., Kochergin I. A., Zakharova M. N. Ectopic lymphoid B-cell follicles in multiple sclerosis: Role in the pathogenesis of the disease and prognostic significance. Journal of Neurology and Psychiatry n.a. S. S. Korsakov. 2019; 119 (10, No. 2): 21–27. https://doi.org/10.17116/jnevro201911910221

The authors declare that there are no conflicts of interest present.